{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T21:15:46Z","timestamp":1721682946790},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":480,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:p>Abstract: We conducted a multi\u2010institutional collaborative study to examine the usefulness and safety of third\u2010generation chemotherapy CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) combined with granulocyte colony\u2010stimulating factor (G\u2010CSF) in the treatment of aggressive non\u2010Hodgkin's lymphoma (NHL). Subjects included patients with aggressive NHL who were 60\u2003yr of age or younger and had been diagnosed as having a low\u2013intermediate, high\u2013intermediate, or high risk using the International Prognostic Index (IPI). A total of 24 patients were enrolled in the study between May 1997 and March 1998, including 9 low\u2013intermediate\u2010risk cases, 13 high\u2013intermediate\u2010risk cases and 2 high\u2010risk cases. Although all 24 patients were originally enrolled in the study, one adult T\u2010cell leukemia\/lymphoma case was subsequently excluded. Thus, in the end, 23 cases were evaluated. Evaluation of the efficacy of therapy revealed complete remission in 20 patients (87%). Of these 20 patients, 8 were low\u2013intermediate\u2010risk cases (89%) and 12 were either high\u2013intermediate\u2010 or high\u2010risk cases (86%). Partial remission was achieved in 2 patients (8.7%). The 2\u2010yr survival rate was 91.3%, and the 2\u2010yr disease\u2010free survival rate was 81.8%. Grade 3 or higher adverse reactions were granulocytopenia (87%), thrombocytopenia (17.4%) and liver dysfunction (4.3%).<\/jats:p><jats:p>\u2003CyclOBEAP therapy has been associated with a high remission rate for aggressive NHL. When combined with G\u2010CSF, a high relative dose intensity was maintained for each drug administered (0.94\u20130.97). Furthermore, although the observation period was short, both the survival rate and disease\u2010free survival rate were good. Hence, we concluded that there were no problems associated with the procedure in terms of safety.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2000.00250.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:50:11Z","timestamp":1047408611000},"page":"188-194","source":"Crossref","is-referenced-by-count":8,"title":["CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony\u2010stimulating factor (G\u2010CSF) for patients with aggressive non\u2010Hodgkin's lymphoma: a pilot study"],"prefix":"10.1111","volume":"65","author":[{"given":"Nozomi","family":"Niitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Kuraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.00250.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.00250.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2000.00250.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:50:05Z","timestamp":1698565805000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2000.00250.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1034\/j.1600-0609.2000.00250.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2000.00250.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}